Alkermes plc - Ordinary Shares (NQ:ALKS)

45.33 -0.04 (-0.09%)

Delayed Quote Updated: 11:43 AM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents. ↗

May 08, 2024

ALKERMES PLC (NASDAQ:ALKS) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

7 Analysts Assess Alkermes: What You Need To Know ↗

May 02, 2024

Via Benzinga

Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS). ↗

May 02, 2024

Should you consider ALKERMES PLC (NASDAQ:ALKS) for growth investing?

Via Chartmill

ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024 ↗

May 01, 2024

ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents. ↗

April 17, 2024

Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.

Via Chartmill

Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS). ↗

April 10, 2024

ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.

Via Chartmill

Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says ↗

April 09, 2024

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2...

Via Benzinga

Breaking Down Alkermes: 5 Analysts Share Their Views ↗

April 09, 2024

Via Benzinga

Is NASDAQ:ALKS suited for growth investing? ↗

March 20, 2024

Is ALKERMES PLC (NASDAQ:ALKS) suited for growth investing?

Via Chartmill

When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

March 27, 2024

When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

The Analyst Verdict: Alkermes In The Eyes Of 4 Experts ↗

March 19, 2024

Via Benzinga

A Look Into Healthcare Sector Value Stocks ↗

March 11, 2024

Via Benzinga

Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗

March 05, 2024

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.

Via Investor's Business Daily

NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases. ↗

March 05, 2024

ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Exploring NASDAQ:ALKS's growth characteristics. ↗

February 28, 2024

Why the growth investor may take a look at NASDAQ:ALKS.

Via Chartmill

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Alkermes's Earnings Outlook ↗

February 14, 2024

Via Benzinga

Is NASDAQ:ALKS suited for growth investing? ↗

February 07, 2024

Why the growth investor may take a look at NASDAQ:ALKS.

Via Chartmill

Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat ↗

February 27, 2024

Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.

Via Investor's Business Daily

Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark ↗

February 23, 2024

Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.

Via Investor's Business Daily

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024 ↗

February 21, 2024

Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.

Via InvestorPlace

Alkermes Stock Gets RS Rating Upgrade; Profits Surge ↗

February 15, 2024

In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday.

Via Investor's Business Daily

CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ ↗

February 13, 2024

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

February 12, 2024

Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents.

Via Chartmill

7 Biotech Stocks Fighting America’s Deadliest Diseases ↗

February 08, 2024

Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.

Via InvestorPlace

Madrigal Pharmaceuticals Stock Shows Rising Relative Strength ↗

February 06, 2024

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

Via Investor's Business Daily

The 3 Best Biotech Stocks to Invest in for Big Gains in 2024 ↗

February 02, 2024

These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns

Via InvestorPlace

3 Top Pharma Stocks to Buy Now: February 2024 ↗

February 01, 2024

Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth.

Via InvestorPlace

For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering. ↗

February 01, 2024

Don't overlook ALKERMES PLC (NASDAQ:ALKS)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating ↗

January 23, 2024

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.